Duchenne Parent Project

Duchenne Parent Project
Name	Duchenne Parent Project
Type	Nonprofit
Founded	2007
Location	Netherlands
Focus	Duchenne muscular dystrophy

Duchenne Parent Project

Duchenne Parent Project is a Dutch nonprofit patient organization established to represent families affected by Duchenne muscular dystrophy. Founded in 2007, it operates within the landscape of rare disease advocacy alongside organizations such as EURORDIS, Muscular Dystrophy Association, Parent Project Muscular Dystrophy, European Commission, and World Health Organization. The foundation engages with academic centers, pharmaceutical firms, patient coalitions, and regulatory agencies including European Medicines Agency, U.S. Food and Drug Administration, and key university hospitals.

History

The organization was created by parents and caregivers influenced by campaigns and models from NHS England collaborations, Fondation Maladies Rares, and grassroots movements like Rare Disease UK and Genetic Alliance UK. Early activities mirrored initiatives from Harvard Medical School clinical networks, Radboud University Medical Center, and patient-driven registries such as TREAT-NMD. It expanded through partnerships with research groups at Leiden University Medical Center, University of Oxford, Utrecht University, and biotechnology firms like Prosensa, Sarepta Therapeutics, and PTC Therapeutics. The group has engaged with policymakers at the European Parliament and participated in conferences hosted by European Academy of Neurology, American Academy of Neurology, and International Rare Diseases Research Consortium.

Mission and Objectives

The foundation’s mission aligns with objectives promoted by United Nations human rights frameworks and health priorities set by World Health Organization rare disease strategies. Core aims include accelerating access to diagnostics and therapies, supporting clinical trial participation with standards from Good Clinical Practice, and promoting patient-centered outcomes used by National Institute for Health and Care Excellence, Institute for Clinical and Economic Review, and academic consortia at Massachusetts General Hospital. Objectives emphasize collaboration with basic science groups at Karolinska Institutet, translational teams at Johns Hopkins University School of Medicine, and regulatory science partners like European Medicines Agency.

Programs and Services

Programs resemble services offered by patient organizations such as Cystic Fibrosis Foundation and Amyotrophic Lateral Sclerosis Association, including patient registries, family support, and education. Services include counseling modeled after programs at Emma Children’s Hospital, training for clinical trial readiness inspired by TREAT-NMD, and information dissemination similar to Muscular Dystrophy Association resources. The organization facilitates workshops with experts from University College London, Cambridge University Hospitals, Erasmus MC, and collaborates with industry partners including Novartis, Roche, and Pfizer for protocol development and access initiatives.

Research Funding and Partnerships

Research funding strategies draw on frameworks used by Wellcome Trust, Bill & Melinda Gates Foundation, and national science councils such as the Netherlands Organisation for Scientific Research. Partnerships include translational collaborations with academic centers at Leiden University Medical Center, VU University Medical Center Amsterdam, and international consortia like TREAT-NMD and International Rare Diseases Research Consortium. The group has supported trial readiness and natural history studies alongside biotech companies such as Sarepta Therapeutics, Ionis Pharmaceuticals, Wave Life Sciences, and contract research organizations linked to IQVIA standards. Grant-making often engages ethics committees associated with European Society for Paediatric Neurology and research funders like Horizon 2020.

Advocacy and Awareness

Advocacy work takes place in arenas frequented by organizations like EURORDIS and Rare Diseases International and involves interactions with legislative bodies including the European Parliament and national ministries of health. The organization runs awareness campaigns akin to those by March of Dimes and coordinates World Duchenne Awareness activities similar to campaigns by World Muscle Society and patient coalitions. It leverages media engagement patterns seen in collaborations with outlets tied to BBC, NOS (Dutch news) and scientific publishers such as Nature and The Lancet to promote policy change, access to care, and newborn screening dialogues involving European Society for Human Genetics.

Organization and Governance

Governance follows nonprofit models comparable to Goodwill Industries International and foundations registered under Dutch law, with a board, advisory panels, and scientific advisory boards featuring clinicians and researchers from Radboud University Medical Center, Leiden University Medical Center, Utrecht University Hospital, and international experts from Johns Hopkins University and Karolinska Institutet. The organization’s structure incorporates patient representatives and family advisory councils similar to those at Parent Project Muscular Dystrophy and Muscular Dystrophy Association to ensure stakeholder engagement and transparency in funding decisions.

Impact and Recognition

The foundation has influenced clinical trial enrollment, registry development, and policy discussions in the European Parliament and national health agencies, contributing to initiatives referenced by European Medicines Agency guidelines and collaborative networks like TREAT-NMD. Recognition parallels awards and acknowledgments given to patient advocacy groups by institutions such as EURORDIS and academic partners including Erasmus MC and Leiden University Medical Center. Its work is cited in collaborative projects with universities, biotech firms, and rare disease coalitions across Europe and North America.

Category:Rare disease organizations Category:Health charities in the Netherlands